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Abstract
Background: Genetically induced hepatocellular carcinoma (HCC) models are generally used to investigate
carcinogenesis pathways, but very few attempts were made to valorize them for pharmacological testing. This
study describes a micro-computed tomography (micro-CT) - based methodology for the diagnostic and lifelong
follow-up of HCC in the hepatocyte-specific Trim24-null mouse line. Myo-inositol trispyrophosphate (ITPP) was
tested as anti-cancer drug.
Methods: Partial hepatectomy was performed in 2 months-old Trim24-null mice, in order to accelerate the
carcinogenesis process. HCC diagnosis was obtained by micro-CT scan with double contrast agent: 10 μl/g
Fenestra™ LC was injected intraperitoneally 6 h prior to imaging and 10 μl/g Fenestra™ VC was injected
intravenously 15 min prior to imaging. Twenty three hepatocyte-specific Trim24-null mice were considered for ITPP
testing (3 mg/g/week intraperitoneally during 10 months in 12 mice, versus 11 controls). Lifelong follow-up was
performed using micro-CT. Comparative analysis was performed using unpaired t test with Welch correction and
survival curves were compared by log-rank test. Gene expression analysis was performed using the RT q-PCR
technique.
Results: Double contrast micro-CT scan allowed HCC diagnosis as hypodense, isodense or hyperdense nodules.
Positive predictive value was 81.3 %. Negative predictive value was 83.3 %. Tumor growth could be objectified by
micro-CT scan before the ITPP treatment was started, and at 3 and 9 months follow-up. Significant progression of
tumor volume was demonstrated in the both groups, with no difference between groups (p > 0.05). In the ITPP group,
a mild decrease in tumor doubling time was first observed (31.9 +/− 12 days, p > 0.05) followed by a significant
increase (59.8 +/− 18.3 days, p = 0.008). However, tumor doubling time was not different between groups (p > 0.05).
Median survival after treatment initiation was 223 days (controls) versus 296 days (ITPP group, p = 0.0027). HIF1α, VEGF,
glutamine synthase, osteopontin expression levels were not significantly modified at the end of follow-up. In the ITPP
group, the p53 expression profile was inversed as compared to the control group, higher in non-tumor livers than in
tumors.
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Conclusion: ITPP treatment allowed for a two-month survival improvement, with better tolerance of tumor burden
and apoptosis increase in non-tumor, pathological livers.
Keywords: High-resolution micro-computed tomography (micro-CT-scan), Genetically induced hepatocellular
carcinoma, Hepatocyte-specific Trim24-null mouse, Transgenic mouse, Myo-inositol trispyrophosphate (ITPP)
Background
Hepatocellular carcinoma (HCC) is the sixth most com-
mon cancer in the world and the second leading cause of
cancer mortality [1]. HCCs’ prognosis is poor due to
chemo and radiotherapy resistance [2, 3]. Consequently,
there is a serious need for new treatment options. Small
animal models are often the only available means of testing
the safety, potency, and efficacy of new anticancer agents
prior to clinical trials. Several types of mouse models of
HCC are available, depending on tumor-inducing mecha-
nisms. For drug development, the most frequently used
models are xenograft models. They are easy to obtain and
follow up, with a rapid growth rate, but their relevance is
limited, as the resemblance between xenograft tumors and
human HCC is rather poor [4]. Additionally, there are
significant differences in tumor growth inhibition between
HCC cell lines [5].
Spontaneous developing tumor models (genetically
engineered mice) are more relevant as tumors occur
through a multistep process of hepatocarcinogenesis. The
natural history is respected (hepatocyte proliferation, dys-
plasia, neoplasia) and HCCs result from the cooperation
and dependency between oncogenes, growth factors and
viral genes [5]. Genetically induced tumor models are gen-
erally used to investigate carcinogenic pathways, but very
few attempts were made to use them for pharmacological
testing.
A hepatocyte-specific Trim24-null mutant mouse line
was used in this study. TRIM24 is a ligand-dependent nu-
clear receptor co-regulator interacting with Retinoic Acid
Receptors (RARs). It was shown to function as a potent
liver-specific tumor suppressor by attenuating RAR alpha
mediated transcription. Indeed, in genetically engineered
mice with silencing of Trim24 gene, an aberrant activation
of RAR alpha, leads to sequentially development of hep-
atocyte alteration, preneoplastic lesions, and HCC [6, 7].
In order to perform pharmacological testing in this spon-
taneously developing HCC model, it was necessary to as-
sess the presence and to ensure the follow-up of intra-
abdominal tumor growth without animal sacrifice.
Micro-computed tomography (micro-CT) for small
animal imaging has been increasingly used over the last
decade [8]. Liver imaging has been obtained with the
enhancement of a radiological agent either through an
ApoE receptor-mediated mechanism or a mechanism of
nanoparticles uptake by the reticuloendothelial system [9].
Both types of contrast agents resulted in variable quality
of liver imaging depending on dose, imaging timing, sub-
jacent liver pathology [10], and even mouse strain [11].
In this study, two main objectives are addressed: first,
to provide a reliable imaging method for spontaneously
developing liver tumors, and secondly, to evaluate the
response to a new anticancer drug, namely myo-inositol
trispyrophosphate (ITPP) [12–14] in the hepatocyte-
specific Trim24-null mutant mouse model.
Methods
Animal models
Hepatocyte-specific Trim24-null mice (Trim24L2/L2Alb-Cre)
A hepatocyte-specific Trim24-null mouse in mixed
C57BL/6 x129/Sv mouse strain was used as a spontan-
eous developing HCC model. As previously described
[6], Trim24-null mice as well as hepatocyte-specific
Trim24L2/L2Alb-Cre [15] develop sequentially abnormal
hypertrophic hepatocytes with enlarged nuclei and in-
creased DNA content and ploidy (3 months of age),
clear-cell foci of altered hepatocytes (7 months), aden-
omas (from 9 months), and invasive hepatocarcinomas
(from 12 months) giving rise to lung metastases.
Wild type mice were 2 months old male littermates
of the Trim24L2/L2Alb-Cre mice.
Partial hepatectomy
Based on the principle of partial hepatectomy (PH) as
promoter of liver carcinogenesis [16], a two-third partial
hepatectomy was performed in Trim24L2/L2Alb-Cre
males at the age of 2 months. Surgery was performed
under isoflurane/oxygen general anesthesia (induction at
3 %, maintaining 1.5 %). A right subcostal laparotomy
was performed. A single silk thread was used for suture
of the left and medial lobes of the liver (constituting
approximately 70 % of the total liver mass) along with
the gallbladder. Gallbladder, left and medial lobes were
resected, followed by careful hemostasis. The abdominal
wall was closed with Vicryl 3/0 separate sutures in two
layers (muscular layer and skin). Animals were allowed
to recover on a 37 °C warm plate.
The early and medium-term effects of PH were evalu-
ated in five groups of 10 mice (5 wild-types and 5
Trim24L2/L2Alb-Cre). Mice were sacrificed at 2 months
Ignat et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:155 Page 2 of 11
of age, and postoperatively at 48 h, 72 h, 5 days, and
15 days respectively after PH. The long-term effect of
PH was evaluated in a group of 6 Trim24L2/L2Alb-Cre
mice, which underwent a PH at the age of 2 months
and were sacrificed postoperatively at 5 months. Livers
were harvested for analysis under isoflurane/oxygen
general anesthesia prior to euthanasia.
HCC xenograft model
This model was obtained as previously described, by means
of an orthotopic injection of a suspension of 2 × 106 Hep
55.1C cells in C57BL/6 J mice [17].
Micro-CT-scan
A small animal micro-scanner X (micro CAT II - Imtek/
Siemens Medical Solutions, Malvern, PA) was used. The
micro CAT II scanner has a single X-ray source and de-
tector technology, and it provides reconstructed images
with a voxel size of 119x119x119μm. The technical pa-
rameters employed were the following: exposure time:
300 milliseconds, X-ray voltage: 80.0 kVp, and anode
current: 500 μA. Micro-CT-scan imaging was performed
under isoflurane general anesthesia and with respiratory
gating. Images were captured after peak expiration,
resulting in a mean scanning time of 15 min. Radio-
logical contrast agents Fenestra™ LC and Fenestra™ VC
(ART Advanced Research Technologies Inc., Montreal,
Canada) consist in polyiodinated lipids, which are select-
ively taken up by hepatocytes via an ApoE receptor-
mediated pathway. Contrast agent injection was per-
formed in conscious mice, placed in a restraining tube
and light heated. In order to prevent volume overload
and liver toxicity (see Additional file 1), contrast agent
dosages, route and timing of administration were estab-
lished as follows: Fenestra™ LC (10 μl/g) intraperitone-
ally, 6 h prior to imaging and Fenestra™ VC (10 μl/g)
intravenously in the tail vein, 15 min prior to imaging.
Micro-CT-scan images exported by the Amira™ 3D soft-
ware were processed with 3D-VPM software (IRCAD,
Strasbourg, France) for 3D reconstruction and to compute
tumor volumes.
To evaluate micro-CT-scan accuracy, a group of 28
Trim24L2/L2Alb-Cre mice aged between 3 and 25 months
were imaged by means of micro-CT-scan, and then
dissected and histologically examined.
HCC follow-up under ITPP treatment - study design
A group of 23 hepatocyte-specific Trim24-null mice was
considered for this study of HCC follow-up under ITPP
treatment (ITPP was a gift from Jean Marie Lehn, ISIS,
Strasbourg, France). All mice had partial hepatectomy at
2 months of age and three successive micro-CT assess-
ments, at 5, 12 and 15–16 months of age. Then, ITPP
treatment was started in 12 mice using an intraperitoneal
injection of 3 mg/g/week over 10 months, and 11
untreated mice were considered as controls. All 23 mice
were imaged by means of micro-CT scan at 3 and
9 months after treatment/survey initiation. 3D reconstruc-
tions of tumor and liver were performed: tumor volumes
were calculated, allowing for the measurement of tumor
doubling time (TDT) [18] and growth rate.
Follow-up was performed until mice were terminally
ill (cachexia, bad grooming, major weakness) or
reached 25 months of age, when the eight surviving
mice (5 in the ITPP group and three in the control
group) were sacrificed. Dissection, macroscopic mea-
surements and sampling for histology and molecular
analysis were performed. Liver and tumor measure-
ments at dissection were corroborated with the last
micro-CT-scan rendering.
Survival curve was constructed over 25 months of age
(average lifespan of wild-type mice).
Animal experiments were approved by the local ethics
committee and were performed according to the revised
European Community directive (2010/63/EU, September
24, 2010) for the protection of animals used for scientific
purposes.
Gross examination, histology, and molecular biology
methods
Gross examination was performed on livers harvested
under isoflurane anesthesia. Livers were weighed first. If
present, the number of tumors, their measurements and
their localization were recorded. Tumor volume was cal-
culated as D1 x D2 X D3 x π/6, where D1, D2 and D3
are tumor diameters.
Histology was performed on tissue samples, fixed in
buffered formaldehyde for 24 h, dehydrated and paraffin-
embedded. Standard 5-μm slides were obtained and
stained by routine Hematoxylin - Eosin (HE) staining.
Slide analysis was performed using the AxioVision 4.6
software (Carl Zeiss MicroImaging GmbH, Göttingen,
Germany).
Ki67 labeling was used for evaluation of proliferation
rate and TUNEL assays (Terminal deoxynucleotidyl
transferase dUTP nick end labeling) for apoptosis
assessment, according to standard procedures. The
percentage of Ki67-positive cells and TUNEL-positive
cells was determined from five randomly chosen fields/
section and three sections/liver for each animal.
Molecular biology
Trim24 genotyping was performed on genomic DNA
obtained from tail biopsy sampled on 10-day-old mice,
by means of a standard PCR technique, using Chromo 4
Thermocycler (Bio-rad, Marnes-la-Coquette, France).
Primers sequences are available in Additional file 2.
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Gene expression analysis in tumor and normal liver
samples was performed using the RT q-PCR technique.
Tissue samples were homogenized in a FastPrep®-24
Instrument (MP Biomedicals Inc., lllkirch, France) in
Lysis Matrix B tubes (MP Biomedicals, Inc.) containing
lysis buffer (Sigma-Aldrich, Saint Quentin Fallavier,
France). RNAs were then purified with the mammalian
GenElute Gel Extraction Kit (Sigma-Aldrich), according
to the manufacturer’s recommendations. RNAs (3 μg)
were used as template for reverse transcription with ran-
dom hexamer and anchored oligo dT, in the presence of
200 units of reverse transcriptase (MP Biomedicals,
Inc.). Resulting cDNAs were analyzed using the RT
qPCR on a Chromo 4 Cycler, using QuanTitect Master-
Mix (Qiagen, Courtaboeuf, France) and the primers cor-
responding to genes of interest (see Additional file 2).
Results were analyzed with the Opticom 3 software (Bio-
rad). Expressions of genes of interest were normalized
by housekeeping gene HPRT and represented as tumor/
liver ratio.
Statistical analysis
Data are expressed as mean ± standard deviation. Com-
parative analysis was performed using a two-way
analysis of variance and unpaired t test with Welch cor-
rection (p < 0.05 was considered statistically significant).
Linear regression equations, confidence intervals, and
log-rank tests were performed using the GraphPad
InStat statistics software (GraphPad Software, Inc., La
Jolla, CA). Correlation between data series was evalu-
ated using Pearson or Spearmen correlation coefficient
as appropriate. The determination coefficient R2 < 0.5
was interpreted as an absence of correlation, and values
close to one as a strong correlation.
Results
Acceleration of hepatocarcinogenesis process by means
of partial hepatectomy (PH)
Early and medium-term consequences of PH were evalu-
ated by relative liver mass measurements, proliferation
and apoptosis levels. Relative liver mass measurements
showed an impaired liver regeneration in Trim24L2/
L2Alb-Cre mice, with 63.3 % of liver mass recovered at
72 h, versus 73.8 % in wild types. The difference was sta-
tistically significant on the overall 15 days period (two
tailed student test, p = 0.034).
Proliferation rate assessment by Ki67 labeling showed
a lower exponential cell cycle entrance at 48 h and lower
proliferation peaks at 72 h in Trim24L2/L2Alb-Cre mice
compared to wild types (p < 0.001 and p = 0.0027 re-
spectively; Fig. 1b). Fifteen days after PH, the prolifera-
tion rate was 8.6 % in Trim24L2/L2Alb-Cre livers, in
favor of prolonged proliferation, as compared to the near
quiescence state (1.3 %) achieved in wild type mice
(Fig. 1b).
Apoptosis level assessment by TUNEL-positive cell
rate was higher in Trim24L2/L2Alb-Cre livers compared
to wild type littermates (p < 0.01, Fig. 1c). Apoptosis
level wasn’t altered following PH in any of the groups
(p > 0.05 compared to baseline, respectively, Fig. 1c).
Long term effect of PH was evaluated 5 months after
surgery. Histology showed the presence of pre-tumor and
tumor lesions: clear cell foci (83 %), adenoma (50 %) and
invasive hepatocarcinoma (16.7 %), compared to 13 %, 0 %
and 0 % in non-operated mice [6] (Fig. 1d, e, f ).
Contrast-enhanced micro-CT-scan imaging of spontan-
eously developing liver tumors
The radiological rendering of liver tumors in Trim24L2/
L2Alb-Cre mice after contrast enhancement showed a
hyperdense, isodense or hypodense nodular or diffuse
mass (Fig. 2).
Hyperdense hypervascular tumors were observed espe-
cially during the early development of the disease and
corresponded to small tumors (Fig. 2a).
Isodense areas with a distinguished vascular enhance-
ment ring (Fig. 2b) were also observed during the early
development of the disease and were consistent with
tumor diagnosis. Isodense tumors represent a real chal-
lenge for diagnosis because there is no difference between
normal and tumor tissue in certain views (frontal/sagittal/
axial). Important arguments in favor of an isodense tumor
are the presence of highly inhomogeneous areas (Fig. 2c,
e, and f) as well as the normal shape disruption of the liver
lobe. Sometimes, a very small disturbance of the normal
anatomy is seen and the presence of some residual peri-
toneal contrast agent might be beneficial and facilitate this
finding, by delineating the tumor’s edges (Fig. 2c and e).
Hypodense areas were observed at all stages of tumor
development and corresponded to less vascularized tu-
mors (Fig. 2c and d). Hypodense areas might otherwise
correspond to central necrosis within larger isodense or
hypervascular tumors (Fig. 2c).
Unlike HCCs developed in xenograft models, which are
constantly visualized on micro-CT-scan as hypodense,
hypovascularized areas (Fig. 3a), the hypodense HCC
present in Trim24L2/L2Alb-Cre mice continue to be well-
vascularized, with a blood supply which can be identified
when thoroughly examining all CT planes (Fig. 3b).
This difference in image rendering by the contrast-
enhanced micro-CT-scan was evaluated using gene ex-
pression profiling.
The levels of Low Density Lipoprotein receptor (LDLR),
which is responsible for Fenestra™ uptake (mediated by
the ApoE receptor), and of VEGF which is responsible for
neovascularization were comparable to the non-tumor
liver in spontaneously developing tumors (p > 0.05) and
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significantly lower in the xenograft model (p = 0.0001 for
LDLR and p = 0.015 for VEGF) (Fig. 3c).
Accuracy evaluation of contrast-enhanced micro-CT-scan
Malignancy detection
In the 28 mice group, micro-CT diagnosis was accurate
in 23 mice. True negative results were obtained on 10
micro-CT-scans. True positive results were obtained on
13 micro-CT-scans.
Two false negative results were recorded for isodense
large tumors. No tumor sign could be prospectively iden-
tified on the micro-CT rendering (see Additional file 3).
Three false positive results were found in three mice
in which the micro-CT-scan showed very small suspect
hypodense areas. Corresponding volumes of suspected
tumors were less than 1 mm3 (i.e., 0.52 mm3, 0.30 mm3
and 0.94 mm3). In these animals, no tumor was found at
dissection or in histology.
The accuracy of micro-CT-scan tumor detection was
82.1 %, with a positive predictive value of 81.3 % and a
negative predictive value of 83.3 %.
Number of tumors and volume evaluation
Findings concerning the number of tumors and total
tumor volume were further compared between micro-
CT-scan imaging and autopsy (confirmed by histological
analysis) in the 13 mice, which were correctly diagnosed
with HCC.
The number of tumors was correctly estimated by
micro-CT-scan (Pearson correlation coefficient r = 0.874,
95 % CI: 0.623-0.961, p < 0.0001) (Fig. 4a).
In one mouse, the two tumors individualized on micro-
CT-scan formed a single tumor upon dissection. In seven
mice bearing multiple disease, there was a slight under-
estimation of tumor number. For these mice, tumor
volume computation was used to evaluate the extent of
the disease. 3D reconstruction of micro-CT-scan render-
ing and tumor volume computation in a dynamic manner
allowed for the most accurate follow-up of tumor mass
progression, in both single tumor and multifocal HCC
(see Additional file 4).
The average computed tumor volumes measured using
micro-CT-scan (832 ± 627 mm3) and autopsy (964 ±
523 mm3) were equivalent (p = 0.15). A highly significant
Fig. 1 Early and late effects of partial hepatectomy (PH) in Trim24L2/L2Alb-Cre mice. a, b, c Early effects of PH in Trim24L2/L2Alb-Cre mice versus
wild type littermates. a Relative liver mass showed impaired and delayed liver regeneration, persistent during at least 15 days in Trim24L2/L2Alb-
Cre groups. Relative liver mass was obtained as following: mean liver mass of mice at the age of 2 months was measured in the first group
(5 mice Trim24L2/L2Alb-Cre and five mice wild type). In the groups sacrificed respectively at 48 h, 72 h, 5 and 15 days, the harvested livers
were weighed and the relative liver mass was calculated as a percentage of the mean liver mass at the age of 2 months. b Ki67 labeling
showed significantly lower proliferation rates at 48 and 72 h after PH with abnormal prolonged proliferation at 15 days after surgery in
Trim24L2/L2Alb-Cre mice. c Apoptosis level (TUNEL labeling) demonstrated a significantly higher level of apoptosis in Trim24L2/L2Alb-Cre
mice, not influenced by the realization of PH. d, e, f Late effect of PH: histological findings (HE staining, original magnification x240) in the
livers of Trim24L2/L2Alb-Cre mice at 5 months after PH. d Clear cell foci (dysplastic hepatocytes, with preserved lobular structure of the liver
and no compression) in 5 out of 6 Trim24L2/L2Alb-Cre mice. e Hepatic adenoma in 3 out of 6 Trim24L2/L2Alb-Cre mice, with no portal
structure within the affected area and compression of neighbouring hepatocyte plates (black arrow heads). f Invasive hepatocarcinoma in 1
out of 6 Trim24L2/L2Alb-Cre mice, with loss of portal structures, carcinoma infiltration of neighbouring hepatocyte plates (black arrowheads)
and numerous mitotic figures as hallmark of malignant lesion (white arrowheads)
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Fig. 2 Micro-CT-scan rendering and corresponding gross appearance of hepatocellular carcinomas (HCC) in Trim24L2/L2Alb-Cre mice. a Hyperdense,
hypervascular nodule in the left liver lobe (arrowhead). b Isodense nodule, with distinguished vascular enhancement ring in the left liver lobe
(arrowheads). c Presence in the right median liver lobe of a hypervascular, isodense nodule [1] and in the left median liver lobe of a
hypodense nodule [2]. d Multifocal HCC with three well-delineated, hypodense nodules [1–3]. e Multifocal HCC with multiple isodense
nodules with an average diameter of 3 to 4 mm; only one tumor [1] located in the right liver lobe had been identified by micro-CT-scan
imaging (vertical diameter shown). f Multifocal HCC with multiple hypodense nodules, isodense nodules and isodense nodules with vascular
enhancement ring [1–7] – 3 mm in diameter, with edges difficult to evaluate by micro-CT-scan imaging and at dissection
Fig. 3 Micro-CT-scan rendering of hepatocellular carcinoma (HCC) in mutant versus xenograft mouse model and corresponding gene expression
levels. a Large hypodense, hypovascularized HCC in orthotopic Hep 55.1c xenograft model in C57BL/6 J mouse (white arrowheads). b Large,
single isodense tumor in Trim24L2/L2Alb-Cre mouse with evident neovascularization network (red arrowheads). c Gene expression of key markers
of lipid uptake capacity (LDLR) and blood network development (VEGF) in HCCs compared to corresponding non-tumor liver expression (fold
expression level +/− standard deviation). In mutant Trim24L2/L2Alb-Cre mice’ HCCs (n = 5) LDLR expression and VEGF and were not significantly
different from non-tumor liver (p = 0.071 and respectively p = 0.56). In orthotopic Hep 55.1c xenografted HCCs (n = 3), LDLR expression was
significantly lower than non-tumor liver (* p = 0.0001), as well as VEGF expression (* p = 0.015)
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correlation was obtained for tumor volume measure-
ments (Pearson correlation coefficient r = 0.90, CI: 0.654
– 0.974, p = 0.0002) using micro-CT-scan examination
when compared to autopsy findings (Fig. 4b).
HCC follow-up under ITPP treatment
In the group of the 23 hepatocyte-specific Trim24-null
mice, no tumors were detected before 5 months of age.
Tumors were detected in 13 mice at 12 months of age
(volume of 18 ± 24 mm3) with no difference in tumor
volume between groups (Fig. 5a).
At 15–16 months, tumors were detected in 18 mice.
There was no difference between tumor volume in the
control group (524 ± 862 mm3) and the ITPP group (106
± 97 mm3, p = 0.24). On the merged group of 23 mice, a
significant tumor growth was observed at this time-point,
as compared to the volumes observed at 12 months of age
(p = 0.043, Fig. 5a). The treatment/survey was initiated at
this time.
Tumor volume follow-up
The follow-up at 3 months showed a tumor volume in
the control group of 1450 ± 1389 mm3 and of 883 ±
934 mm3 in the ITPP group (p = 0.36, Fig. 5a). During
this period, three animals died in the control group
and one animal died in the ITPP group. When consid-
ering tumor burden in live animals, a significant
increase in tumor volume was demonstrated in the
control group (from 511.4 ± 869.8 mm3 to 1450 ±
1389 mm3, p = 0.034) and in the ITPP group (96 ±
97.7 mm3 to 883 ± 934 mm3, p = 0.008).
Mean tumor volume was subject to a high variance.
The follow-up at 9 months showed a tumor volume
in the control group of 543 ± 134 mm3 and of 1214 ±
566 mm3 in the ITPP group (p = 0.076, Fig. 5a). Five an-
imals bearing large tumors died in the control group
and six animals in the ITPP group. When considering
tumor burden in live animals, a significant increase in
tumor volume was demonstrated in the control group
(from 163.3 ± 224 mm3 to 543 ± mm3, p = 0.041) and in
the ITPP group (from 179.5 ± 128.2 mm3 to 1214 ±
566 mm3, p = 0.005).
Tumor doubling time
No difference was observed in TDT before treatment in
the ITPP group (51 +/− 24 days) versus the control
group (44 +/− 10.9 days, p = 0.28, Fig. 5b).
In the control group, a mild increase in TDT was
observed during follow-up (p > 0.05) corresponding to a
less rapid tumor growth in the later stages of HCC
development (Fig. 5b).
In the ITPP group, a mild decrease in TDT was
observed at 3 months of treatment (31.9 +/− 12 days,
p > 0.05) followed by a significant increase in TDT at
9 months (59.8 +/− 18.3 days, p = 0.008), with return to
pre-treatment values (Fig. 5b).
No significant difference was observed in TDT between
the ITPP group and the control group, at any time point.
Survival curve
Overall survival of control animals was 658 +/− 111 days
(with an average of 205 ± 113 days of controlled survey).
Fig. 4 Evaluation of micro-CT-scan accuracy. a Correlation between identified tumor number by micro-CT-scan (X axis) and at autopsy (Y axis)
follows a linear regression model. The tumor number is accurately predicted only for a small number of tumors (i.e. <3). b Correlation between
estimated tumor volume by micro-CT-scan (X axis) and at autopsy (Y axis) follows a linear regression model. The regression slope of 0.82 corresponded
to a slight underestimation of micro-CT-scan volumes, probably due to physiological organ compression in the living animal
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Overall survival in the ITPP group was 720 +/− 87 days,
with an average of 265 ± 76 days of ITPP treatment, corre-
sponding to a 2-month prolongation of lifespan (Fig. 5c).
Log-rank comparison demonstrated an improved survival
in the ITPP group (p = 0.0027).
Molecular findings
Expression levels of marker genes for the main pathways
of carcinogenesis and angiogenesis were investigated in
tumor and non-tumor livers, at the end of the follow-up.
Hypoxia pathways were not repressed: HIF1α and
VEGF gene expression levels in the liver and tumors was
not modified in the ITPP group versus the control group
(Fig. 5d). VEGF expression level demonstrated a 2.5-fold
increase in the treated tumors (p = 0.26).
The expression level of p53 was assessed. In the con-
trol group, an over-expression of p53 was recorded in
tumors (2.7 +/− 0.3) as compared to livers (1 +/− 0.27,
p = 0.004). In the ITPP group, the expression profile of
the p53 expression was inversed, with a higher expres-
sion in livers than in tumors (4.23 +/−3.06, versus 2.1 ±
1.3, p > 0.05).
Other carcinogenesis and inflammation markers (glu-
tamine synthase, osteopontin) were not significantly modi-
fied (Fig. 5d).
Discussion
The major interest of transgenic mouse models of HCC
is that tumor development reflects the clinical reality:
pathological liver background, natural tumor - liver
interactions, and well-vascularized tumors. This in vivo
animal study valorized the genetic knowledge on the
Trim24 gene, which had enabled the engineering of a
HCC mouse model - Trim24L2/L2Alb-Cre. In practice, to
Fig. 5 Hepatocellular carcinoma (HCC) follow-up under myo-inositol trispyrophosphate (ITPP) treatment (red) versus control group (blue) of
hepatocyte-specific Trim24-null mice. a Follow-up of tumor volumes by micro-CT-scan imaging. Logarithmic scale was employed in order to cover
the entire volume range. No significant difference was observed between the tumor volumes in the ITPP group and in the control group at any
time point. Before treatment started (12 to 15–16 months), there was a significant progression in tumor volume in both groups (*black, p = 0.043).
At 3 and 9 months after the treatment started (15–16 to 18–19 months), the tumor burden in live animals was in significant progression in the
control group (*blue) and in ITPP group (*red). b Tumor doubling time (TDT), on the basis of tumor volumes obtained by micro-CT. No difference
was observed in TDT between the ITPP group and the control group, at any time point. In the ITPP group, mild tumor growth acceleration was
observed at 3 months of treatment with significant deceleration at 9 months (p = 0.008). c Survival curves. Median survival interval was 296 days
in the ITPP group and 223 days in the control group corresponding to a 2-month prolongation of life span. Log-rank comparison demonstrated
improved survival in the ITPP group (p = 0.0027). d Gene expression level in tumor (full bars) and non-tumor livers (motif bars) in sacrificed
hepatocyte-specific Trim24-null mice, at the end of the follow-up period. Data were expressed as average fold expression +/− standard deviation.
In the control group, the p53 expression level was significantly higher in tumor over non-tumor liver (*blue, p < 0.05)
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test an anticancer agent in a genetically induced model
presents reputable disadvantages: long tumor developing
time, unpredictability of tumor development, and non-
homogeneity of the model. In order to challenge these
shortcomings, a step-by-step methodology was described
in this study.
First, evidence was provided that PH resulted in pro-
longed cell-cycling, with significantly high proliferation
rate, beyond 15 days after PH and resulting in earlier de-
velopment of HCC at long term follow-up. Based on this
finding, PH was systematically performed in all animals,
in order to boost the hepatocarcinogenesis process.
In order to assess the presence and to ensure the
follow-up of HCC in Trim24L2/L2Alb-Cre mice, a
contrast-enhanced micro-CT-scan imaging protocol was
created. Several issues needed to be addressed: under-
standing of the particular rendering of the spontaneously
developed tumors, coping with repeated contrast agent
injection on the pathological liver background and with
toxicity of the contrast agent. Data from the literature
are mainly based on graft model imaging, in which the
high resolution of the micro-CT-scan, along with specif-
ically developed contrast agents [9, 10, 19, 20] allowed
to detect liver tumors starting with a 300 μm diameter
[9, 10], to calculate in vivo tumor volume [21], and to
monitor disease progression [22, 23]. Monitoring of
drug/therapy efficacy using micro-CT-scan was shown
to be feasible in orthotropic models [24, 25] and in a
pilot study in three transgenic ASV-B mice [10]. In these
studies, HCCs were visualized as non-enhanced areas on
the background of the normal, contrast-enhanced liver
parenchyma. These renderings are consistent with our
team’s experience in xenograft tumor models (Fig. 3a).
However, they were not confirmed for spontaneously
developing tumors in Trim24L2/L2Alb-Cre mice, in
which the rendering of HCC was much more poly-
morphic (i.e., hypodense, isodense or hyperdense nod-
ules and diffuse mass).
In the present study, a contrast agent injection protocol
was described, consisting in an intraperitoneal contrast
agent injection 6 h before imaging and vascular agent in-
jection 15 min prior to imaging. This protocol allowed for
the optimal visualization of spontaneously developing liver
tumors, with low toxicity, adapted to the pathological liver
background. Diagnosis of liver malignancy was achieved
with an accuracy of 82.1 %, comparable to that obtained
in prospective clinical trials [26].
Finally, ITPP was pharmacologically tested in
Trim24L2/L2Alb-Cre spontaneous HCC model. ITPP is
a synthetic allosteric effector of hemoglobin, which in-
creases the oxygen-releasing capacity of red blood cells
leading to the suppression of hypoxia-inducible factors and
to the down-regulation of hypoxia-inducible genes. Conse-
quently, tumor growth is markedly affected in hypoxic
tumors [12]. ITPP proved its anticancer efficacy in graft
models of melanoma and breast cancer [12], colon cancer
[13], pancreatic cancer [14], and hepatoma [25]. In the
present setting, the non-invasive imaging approach allowed
to collect comprehensive data on tumor growth rate, sur-
vival and molecular findings with minimal animal sacrifice.
Tumor growth could be objectified before the ITPP
treatment was started, and at the 3 and 9 months
follow-up. Significant progression of tumor burden was
equally demonstrated in the control group as well as in
the ITPP group with no difference between groups.
However, when further analyzing TDT, a mild acceler-
ation of tumor growth (decrease of TDT) at 3 months of
ITPP treatment was observed, with return to initial
growth rate at 9 months of follow-up. Tumor growth ac-
celeration seemed to be in contradiction with previous
data [25]. It was nevertheless consistent with molecular
findings, which could not demonstrate HIF1a and VEGF
suppression at the end of the follow-up period. These
findings were probably the consequence of the more im-
portant vascularization of tumors, as compared to graft
models. In this genetically induced model, in which he-
patocytes are continuously cell cycling, hypoxia might be
of minimum importance in the neoplastic development,
and subsequently the efficacy of the treatment on tumor
burden is of less importance. In return, in the ITPP
group, tumors were better tolerated, mice continuing to
survive despite very large tumors and a low volume of
functional livers. In the ITPP group, treatment seemed
to protect against the onset of new HCCs, as suggested
by higher levels of p53 in non-tumor livers. This could
account for the long-term effects of the product, with a
significant prolongation of survival, which favored the
ITPP treatment.
Conclusion
Double contrast micro-CT scan approach allowed tumor
detection and lifelong follow-up of the spontaneously de-
veloping HCC in Trim24L2/L2Alb-Cre mice. Intention-to-
treat pharmacological testing of ITPP was performed with
a minimum number of mutant animals and resulted in a
2 months prolongation of lifespan in the ITPP group, des-
pite progressive increase in tumor burden in both groups.
Additional files
Additional file 1: Fenestra™ toxicity. Table: Liver function tests,
expressed as average ± standard deviation, in a 20 mice group (16 wild
types and 4 mice Trim24L2/L2Alb-Cre) receiving a total dose of up to
22 μl/g Fenestra™) controlled by five wild type mice receiving no
Fenestra™ ASAT: aspartate transaminase, ALAT: alanine transaminase, GGT:
gamma-glutamyl transferase. Alkaline phoshpatase levels were not
different. Serological measurements (ASAT, ALAT, bilirubin, GGT, alkaline
phoshpatase) were performed on blood samples collected by direct
cardiac puncture under general isoflurane anaesthesia before animal
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euthanasia. Standard techniques (ADVIA 2400, Siemens and immune-
nephelometry BNII) were employed. Figure: Micrographs of histological
structure of the liver (A, B, C) and kidney (D) in mice with acute toxicity
after 22 μl/g Fenestra™ administration. HE staining, original magnifica-
tions x1500 (A, B) and x240 (C, D). Red arrows: leucocyte adhesion and
diapedesis; Arrowheads: hepatocyte necrosis; White arrows: periportal
or centrolobular inflammatory infiltrate; Black arrows: acute tubular
necrosis. (DOC 8191 kb)
Additional file 2: Gene primers. A. Primers used for Trim24 genotyping.
B. Primers used for qPCR. (DOC 34 kb)
Additional file 3: False negative results in microCT scan imaging in two
mice. A, B, C. Aspects corresponding to the first animal. A, B. Axial and
frontal view of microCT scan imaging of an isodense, poorly delineated
right liver lobe tumor. Prospective and retrospective interpretation of
images could only identify an enlargement of the right liver lobe. The
border between normal and pathological tissue could not be identified
on the microCT scan rendering. C. Gross appearance of the poorly
delineated right liver lobe tumor, depicted in A and B. D, E, F. Aspects
corresponding to the second animal. D. Retrospective interpretation of
microCT scan rendering with identification of a centroabdominal in-
homogeneous, isodense tumor (arrowheads). E. Gross appearance of the
centroabdominal tumor which was not identified at the prospective in-
terpretation of the microCT scan images. F. Histological assessment of
the presence of a hepatocellular carcinoma (HE, x240). (JPG 3580 kb)
Additional file 4: Follow-up of hepatocellular carcinoma (HCC) growth
by 3D reconstruction. Follow-up of hepatocellular carcinoma (HCC)
growth by 3D reconstruction of micro-CT rendering. Micro-CT imaging
was performed at 12, 15, and 21 months of age respectively in hepatocyte
specific Trim24-null mice. A, B, C Exponential growth of unifocal HCC. A.
Micro-CT-scan rendering in coronal slides (strips indicate vertical diameter of
HCC). B. 3D reconstruction of the micro-CT-scan (HCC is depicted in green).
C. Macroscopic appearance of the liver and HCC at dissection at 22 months
old (black arrow indicates tumor). D, E, F. Multifocal growth of HCC. D.
Micro-CT scan rendering in coronal slides (strips indicate vertical diameters
of the HCCs). E. 3D reconstruction of the micro-CT-scan (HCCs are depicted
in green). F. Macroscopic appearance of the liver and HCCs at dissection at
23 months old (black arrows indicate tumors). (JPG 4259 kb)
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